Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Tissue Engineering & Bioprinting: Research to Commercialization

Todd McAllister's Biography

Todd McAllister, President & CEO, Cytograft Tissue Engineering, Inc.

Dr. McAllister is the co-founder and CEO of Cytograft Tissue Engineering, Inc., a cardiovascular regenerative medicine company developing cell-based therapies to repair and rebuild diseased tissues and organs without using synthetic biomaterials. He has a B.S degree in Mechanical Engineering from the University of Washington, and a Ph.D. in Biomedical Engineering from the University of California, San Diego. Dr. McAllister pioneered a novel business strategy that prioritized capital efficiency and research focus. Over the span of 6 years, Cytograft was able to transition from inception to Phase II clinical trials, and is moving programs forward based on its proprietary platform, “TESA™,” Tissue Engineering by Self Assembly™. Cytograft is now one of the few Regenerative Medicine companies pursuing Phase IIb/III clinical trials. The Company has a broad platform of therapeutic indications with vascular grafts, valve leaflets, covered stents, and dermal fillers that are under development.
With more than two decades of experience, Dr. McAllister is a well-known thought leader in the field of Regenerative Medicine. He is a frequent reviewer and contributor for high impact journals and is on the editorial board of the Journal of Biofabrication and on the Industry Committee for the Journal of Tissue Engineering. He is on the Executive Board for the International Cell Medicine Society. Dr. McAllister has also sat as a reviewer or external advisory board member for AFIRM, NIH, and NSF EPSCOR grants. He has sat on the advisory boards of several companies, including BioCardia, Lumen Therapeutics, Wolf Biosciences and others. Dr. McAllister’s was also the co-Director of the Center for Regenerative Medicine at the St. Joseph’s Translational Research Institute in Atlanta, Georgia, where he oversaw a broader range of cell-based cardiovascular repair technologies.

Todd McAllister Image

Commercialization Challenges in Regenerative Medicine: How do we fund companies that take decades to develop successful clinical treatments?

Monday, 9 February 2015 at 14:15

Add to Calendar ▼

Few people would doubt the potential of cell-based therapies and Regenerative Medicine.  Despite the promise of the field, however, few companies have been able to harness the power of the cell and translate that into a successful commercial venture.  As an increasing number of clinical and commercial successes are being demonstrated, what lessons can be learned?  Specific successes and failures will be discussed in an effort to identify common elements that can push your company toward not just clinical success, but commercial success as well.

Add to Calendar ▼2015-02-09 00:00:002015-02-10 00:00:00Europe/LondonTissue Engineering and Bioprinting: Research to CommercializationTissue Engineering and Bioprinting: Research to Commercialization in Boston, USABoston,